The normobaric oxygen paradox: A novel way to administer oxygen as an adjuvant treatment for cancer?

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 467-470

  De Bels, D ^a,b   Corazza, F ^a   Germonpre P ^b,c   Balestra, C ^b  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b Haute Ecole Bruxelles Brabant   (Belgium)

^c QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; OXYGEN; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW HYPOPLASIA; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INHIBITION; CELL PROTECTION; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATORY CELL; INTRACELLULAR SIGNALING; MACROPHAGE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; OXYGEN TENSION; OXYGEN THERAPY; PROTEIN INDUCTION; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ADMINISTRATION, INHALATION; CHEMOTHERAPY, ADJUVANT; ERYTHROPOIETIN; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952315399     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.11.022     Document Type: Article

References (26)

1. Hotchkiss R.S., Strasser A., McDunn J.E., Swanson P.E. Cell death. N Engl J Med 2009, 361:1570-1583.
2. Burk R. Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO). Med Hyp 2007, 69:1200-1204.
3. Balestra C., Germonpre P., Ciccarella Y., Lafere P., Van der Linden P. The "Normobaric Oxygen Paradox": a simple way to induce endogenous EPO production and concomitantly Hb in anemic patients. Transfu Altern Transfu Med 2010, 11:39-42.
4. Balestra C., Germonpre P. EPO and doping. Eur J Appl Physiol 2010, 190(5):1001-1002.
5. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001, 20:5197-5206.
6. Haddad J.J. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002, 14:879-897.
7. Haddad J.J., Land S.C. O(2)-evoked regulation of HIF-1alpha and NF-kappaB in perinatal lung epithelium requires glutathione biosynthesis. Am J Physiol Lung Cell Mol Physiol 2000, 278:L492-503.
8. Paschos N., Lykissas M.G., Beris A.E. The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci 2008, 4:161-168.
9. Hare G.M., Tsui A.K., McLaren A.T., Ragoonanan T.E., Yu J., Mazer C.D. Anemia and cerebral outcomes: many questions, fewer answers. Anesth Analg 2008, 107:1356-1370.
10. Lipsic E., Schoemaker R.G., van der Meer P., Voors A.A., Schoemaker R.G., Veldhuisen D.J., et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006, 48:2161-2167.
11. Weidemann A., Johnson R.S. Biology of HIF-1alpha. Cell Death Differ 2008, 15:621-627.
12. Adamcio B., Sperling S., Hagemeyer N., Walkinshaw G., Ehrenreich H. Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice. Behav Brain Res 2010, 208:80-84.
13. Huang J.H., Lee F.S., Pasha T.L., Sammel M.D., Karakousis G., Xu G., et al. Analysis of HIF-1alpha and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications. Cancer Biol Ther 2010, 9.
14. Koukourakis M.I., Giatromanolaki A., Chong W., Simopoulos C., Polychronidis A., Sivridis E., et al. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. Cancer Chemother Pharmacol 2004, 53:8-14.
15. Raa A., Stansberg C., Steen V.M., Bjerkvig R., Reed R.K., Stuhr L.E. Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer 2007, 7:23.
16. Balestra C., Germonpre P., Poortmans J.R., Marroni A. Serum erythropoietin levels in healthy humans after a short period of normobaric and hyperbaric oxygen breathing: the "normobaric oxygen paradox" J Appl Physiol 2006, 100:512-518.
17. Nizet V., Johnson R.S. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol 2009, 9:609-617.
18. Hart C., Grassinger J., Andreesen R., Hennemann B. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. Bone Marrow Transplant 2009, 43:197-206.
19. Tsuboi M., Ezaki K., Tobinai K., Ohashi Y., Saijo N. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. Jpn J Clin Oncol 2009, 39:163-168.
20. Warm M., Kates R., Dick M., Thomas A., Mallmann P., Hoopmann M., et al. Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer. Oncol Rep 2009, 21:777-785.
21. Spivak J.L., Gascon P., Ludwig H. Anemia management in oncology and hematology. Oncologist 2009, 14(Suppl. 1):43-56.
22. Elliott S., Busse L., Bass M.B., Lu H., Sarosi I., Sinclair A.M., et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006, 107:1892-1895.
23. Henke M., Verma A., Acs G. Erythropoietin receptors on cancer cells: exciting perspectives, difficult to appreciate. Blood 2006, 108:1107-1108. Author reply 1108-1109.
24. Balendiran G.K., Dabur R., Fraser D. The role of glutathione in cancer. Cell Biochem Funct 2004, 22:343-352.
25. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 2006, 43:143-181.
26. Li W.S., Lam W.S., Liu K.C., Wang C.H., Chang H.C., Jen Y.C., et al. Overcoming the drug resistance in breast cancer cells by rational design of efficient glutathione S-transferase inhibitors. Org Lett 2010, 12:20-23.